Article: P2.05 Global HDAC enzymatic activity is a strong marker of poor prognosis in Chronic Lymphocytic Leukemia

Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma